<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754532</url>
  </required_header>
  <id_info>
    <org_study_id>SHA-12-0028</org_study_id>
    <nct_id>NCT01754532</nct_id>
  </id_info>
  <brief_title>Correlation Between Clinical Deterioration in Schizophrenic Patients and Hair Cortisol Levels</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The importance of stress as a possible deteriorating factor for schizophrenic patients is&#xD;
      well documented. However, this notion is based on subjective experience and retrospective&#xD;
      psychological analysis.&#xD;
&#xD;
      A novel method of measuring cortisol using hair has a proven correlation to subjective stress&#xD;
      in non-clinical as well as psychiatric clinical populations.&#xD;
&#xD;
      This pilot study will attempt to assess the use of cortisol hair level, as a marker of&#xD;
      stress, to predict clinical deterioration in schizophrenic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Positive And Negative Symptoms Score</measure>
    <time_frame>3 month</time_frame>
    <description>correlation between hair cortisol level change from baseline and PANSS score change from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Positive And Negative Symptoms Score</measure>
    <time_frame>6 month</time_frame>
    <description>correlation between hair cortisol level change from baseline and PANSS score change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SANS, CGI, CDS, GAF and QOL Scores</measure>
    <time_frame>3 month</time_frame>
    <description>correlation between hair cortisol level change from baseline and SANS, CDS, GAF, CGI, and QOL scores change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SANS, CGI, CDS, GAF and QOL Scores</measure>
    <time_frame>6 month</time_frame>
    <description>correlation between hair cortisol level change from baseline and SANS, CDS, GAF, CGI, and QOL scores change from baseline.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">34</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizo-Affective Disorder</condition>
  <arm_group>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hair Sample</intervention_name>
    <description>Analysis of hair cortisol levels</description>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10mg of posterior vertex hair&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Schizophrenia or Schizo-Affective Disorder&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-50&#xD;
&#xD;
          -  Diagnosis of schizophrenia or schizoaffective disorder, made by a senior psychiatrist.&#xD;
&#xD;
          -  Signing an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Additional psychiatric diagnosis&#xD;
&#xD;
          -  Boldness or hair shorter than 1cm&#xD;
&#xD;
          -  Physiological disturbance in the HPA or the use of steroidal medication&#xD;
&#xD;
          -  Neurological disease (past or present) or neurosurgery.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Substantial chronic physical diseases/&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aviv Segev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata MHC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shalvata MHC</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shalvata Mental Health Center</investigator_affiliation>
    <investigator_full_name>Aviv Segev</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizo-Affective Disorder</keyword>
  <keyword>Stress</keyword>
  <keyword>Cortisol</keyword>
  <keyword>PANSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

